over 17,200 people with hemophilia have been treated
In the past five years, there has been a life-changing impact a reliable supply of factor therapy can have for people in developing countries; access to prophylactic treatment for children, corrective surgeries, all helping to reduce the burden of Haemophilia. Sobi and Sanofi together with the World Federation of Hemophilia (WFH) and WFH USA extended their support of the WFH Humanitarian Aid Program. Both added a donation of up to 500 million IUs of factor therapy for humanitarian fulfilling the 2014 pledge to donate up to an unprecedented 1 billion IUs over a ten-year period.
The previous donation of medicine to the program, over 450 million IUs, and over 17,200 people with hemophilia have been treated with factor donated by Sobi and Sanofi between 2015 and 2019. In addition, the companies will continue to provide financial support for initiatives such as treatment, access, and education programs for a period of up to five years.
Significant unmet need in developing world
In developing countries, more than 75 percent of people with hemophilia have limited or no access to diagnosis and treatment. People with severe hemophilia in these countries often do not survive to adulthood; those who do, often face a life of severe disability, isolation, and chronic pain.
A predictable supply of factor therapy is essential to improving treatment and care. Education programs for treaters and patients are critical initiatives helping to develop in-country capacities to improve diagnosis and treatment monitoring. They only needed to create a sustainable treatment environment that leads to better outcomes for patients.
A far-reaching impact on hemophilia care
With the provision of a consistent supply of factors, corrective surgeries and prophylaxis treatment for young children have become possible. Since initial shipments of Sobi and Sanofi medicines to the WFH Humanitarian Aid Program began, the impact has been far-reaching. Through 2019:
- 450 million IUs of clotting factor has treated over 17,200 people in 42 countries
- 900 children under the age of 10 are receiving prophylaxis treatment
- More than 160,000 acute bleeds have been treated
- More than 2,300 surgeries have taken place including those that were life- and limb-saving.
